Now Playing
Opinion|Videos|April 22, 2024
Approved Bispecifics for the Treatment of Relapsed/Refractory Multiple Myeloma (R/R MM)
Author(s)Caitlin Costello, MD, Matthew James Pianko, MD
Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
4
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
5